UK-based drug company Summit Corp plc. (SUMM.L) Tuesday said it entered into a technology-license agreement with Bristol-Myers Squibb. Summit's Seglin technology, which develops drug candidates for up to ten targets across multiple therapeutic areas, is of interest to Squibb, which will pay a $100 thousand technology access fee plus regulatory milestones of up to $30 million per product synthesized to Summit.
Bristol-Myers Squibb shall take responsiblity for the discovery stage of the research and have exclusive rights to develop and commercialize all Seglin products identified, said Summit in a statement.
The stock is currently trading at 2.50 pence, up 0.13 pence or 5.26 percent on the LSE.
Click here to receive FREE breaking news email alerts for Summit Corp. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org